Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials

Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials Publisher Pubmed

Talasaz AH^{1, 2, 3} ; Sadeghipour P⁴ ; Aghakouchakzadeh M¹ ; Kakavand H¹ ; Ariannejad H² ; Connors JM⁵ ; Hunt BJ⁶ ; Berger JS⁷ ; Van Tassell BW^{3, 8} ; Middeldorp S⁹ ; Piazza G¹⁰ ; Weitz JI^{11, 12} ; Cushman M^{13, 14} ; Lip GYH^{15, 16} Show All Authors

Talasaz AH^{1, 2, 3}
Sadeghipour P⁴
Aghakouchakzadeh M¹
Kakavand H¹
Ariannejad H²
Connors JM⁵
Hunt BJ⁶
Berger JS⁷
Van Tassell BW^{3, 8}
Middeldorp S⁹
Piazza G¹⁰
Weitz JI^{11, 12}
Cushman M^{13, 14}
Lip GYH^{15, 16}
Goldhaber SZ¹⁰
Bikdeli B^{10, 17, 18}

Source: Journal of Thrombosis and Haemostasis Published:2021

Abstract

Background: Coronavirus disease 2019 (COVID-19) is associated with macro- and micro-thromboses, which are triggered by endothelial cell activation, coagulopathy, and uncontrolled inflammatory response. Conventional antithrombotic agents are under assessment in dozens of randomized controlled trials (RCTs) in patients with COVID-19, with preliminary results not demonstrating benefit in several studies. Objectives: Given the possibility that more novel agents with antithrombotic effects may have a potential utility for management of patients with COVID-19, we assessed ongoing RCTs including these agents with their potential mechanism of action in this population. Methods: We searched clinicaltrials.gov and the World Health Organization International Clinical Trials Registry Platform to identify RCTs of novel antithrombotic agents in patients with COVID-19. Results: Based on a systematic literature search, 27 RCTs with 10 novel antithrombotic agents (including nafamostat, dociparstat, rNAPc2, and defibrotide) were identified. The results from these trials have not been disseminated yet. The studied drugs in the ongoing or completed RCTs include agents affecting the coagulation cascade, drugs affecting endothelial activation, and mixed acting agents. Their postulated antithrombotic mechanisms of action and their potential impact on patient management are summarized. Conclusion: Some novel antithrombotic agents have pleiotropic anti-inflammatory and antiviral effects, which may help reduce the viral load or fibrosis, and improve oxygenation. Results from ongoing RCTs will elucidate their actual role in the management of patients with COVID-19. © 2021 International Society on Thrombosis and Haemostasis

Related Docs

View other Related Docs

1. Covid-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment, Seminars in Thrombosis and Hemostasis (2023)

2. Intermediate-Dose Versus Standard-Dose Prophylactic Anticoagulation in Patients With Covid-19 Admitted to the Intensive Care Unit: 90-Day Results From the Inspiration Randomized Trial, Thrombosis and Haemostasis (2021)

3. Knowledge Gaps for Prophylactic Use of Antithrombotic Agents in Patients With Covid-19: Insights Into New Sars-Cov-2 Variants, Vaccination Status, and Emerging Oral Antivirals, Thrombosis and Haemostasis (2023)

Experts (# of related papers)

View all Related Experts

Azita Hajhossein Talasaz (8)

Mohammad Taghi Beigmohammadi (4)

Style	Citing Format
MLA	Talasaz AH, et al.. "Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials." Journal of Thrombosis and Haemostasis, vol. 19, no. 12, 2021, pp. 3080-3089.
APA	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, Berger JS, Van Tassell BW, Middeldorp S, Piazza G, Weitz JI, Cushman M, Lip GYH, Goldhaber SZ, Bikdeli B (2021). Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials. Journal of Thrombosis and Haemostasis, 19(12), 3080-3089.
Chicago	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, Hunt BJ, et al.. "Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials." Journal of Thrombosis and Haemostasis 19, no. 12 (2021): 3080-3089.
Harvard	Talasaz AH et al. (2021) 'Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials', Journal of Thrombosis and Haemostasis, 19(12), pp. 3080-3089.
Vancouver	Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, Kakavand H, Ariannejad H, Connors JM, et al.. Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials. Journal of Thrombosis and Haemostasis. 2021;19(12):3080-3089.
BibTex	@article{ author = {Talasaz AH and Sadeghipour P and Aghakouchakzadeh M and Kakavand H and Ariannejad H and Connors JM and Hunt BJ and Berger JS and Van Tassell BW and Middeldorp S and Piazza G and Weitz JI and Cushman M and Lip GYH and Goldhaber SZ and Bikdeli B}, title = {Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials}, journal = {Journal of Thrombosis and Haemostasis}, volume = {19}, number = {12}, pages = {3080-3089}, year = {2021} }
RIS	TY - JOUR AU - Talasaz AH AU - Sadeghipour P AU - Aghakouchakzadeh M AU - Kakavand H AU - Ariannejad H AU - Connors JM AU - Hunt BJ AU - Berger JS AU - Van Tassell BW AU - Middeldorp S AU - Piazza G AU - Weitz JI AU - Cushman M AU - Lip GYH AU - Goldhaber SZ AU - Bikdeli B TI - Use of Novel Antithrombotic Agents for Covid-19: Systematic Summary of Ongoing Randomized Controlled Trials JO - Journal of Thrombosis and Haemostasis VL - 19 IS - 12 SP - 3080 EP - 3089 PY - 2021 ER -

Science Communicator Platform

Authors

Abstract